Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Regulatory News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.15
Bid: 2.06
Ask: 2.20
Change: -0.015 (-0.70%)
Spread: 0.14 (6.796%)
Open: 2.10
High: 2.15
Low: 2.10
Prev. Close: 2.145
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directors' Dealings

23 Jul 2009 16:17

RNS Number : 2020W
Immupharma PLC
23 July 2009
 



For Immediate Release

23 July 2009

ImmuPharma PLC

Directors' Dealings

Institutions increase stake

 

ImmuPharma PLC ('ImmuPharma' or the 'Company') (LSE:IMM) announces that a number of existing and new blue-chip institutional investors have purchased shares from Richard Warr and the Trusts of Richard Warr and Dimitri Dimitriou, who are two of ImmuPharma's founders and Directors.  A total of 12.5 million ordinary shares (16.1% of the issued share capital) of 10 pence each in the Company, were placed by Noble & Company Limited at a price of 86 pence per share to institutional investors on 23 July 2009. Panmure Gordon is the NOMAD and Corporate Broker to the Company. 

 

Following the disposal, the current holdings directly or through Trust are:

Ordinary Shares Sold

Ordinary Shares Retained

Percentage  of shares in issue

Richard Warr (1)

6,250,000

3,528,968

4.6%

Dimitri Dimitriou (2)

6,250,000

3,528,969

4.6%

Dr Zimmer & Family

0

23,056,602

29.8%

 

(1)  Ordinary shares of £0.10 held by Louvre Trustees Limited where the Warr family has a beneficial interest and shares held directly by Richard Warr

 

(2)  Ordinary shares of £0.10 held by Louvre Trustees Limited where the Dimitriou family has a beneficial interest. 

 

Richard Warr, ImmuPharma's Chairman said: "We are delighted with the support received from our existing investors and the demand from new investors including M&G Investments.  The allocation of these shares further increases ImmuPharma's free float with the aim of improving overall liquidity."

 

For further information please contact: 

ImmuPharma PLC

+44 20 7152 4080

Dimitri Dimitriou, Chief Executive Officer 

Richard Warr, Chairman

Panmure Gordon

+44 151 243 0963

Andrew Burnett/ Rakesh Sharma 

Noble & Company Limited

+44 20 7763 2335

John Millar

Buchanan Communications

+44 20 7466 5000

Lisa Baderoon 

Rebecca Skye Dietrich

More information on the Company can be found at www.immupharma.com 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSSELFIDSUSEFW
Date   Source Headline
4th Jun 20197:00 amRNSNotice of AGM and posting of Report & Accounts
24th May 20197:00 amRNSFINAL RESULTS
7th May 20197:00 amRNSCorporate Update
1st Apr 20197:00 amRNSUpdate on Nucant Cancer Programme
14th Mar 20197:00 amRNSCorporate Update
26th Feb 20197:00 amRNSTechnology review published-Nature Communications
31st Dec 20187:00 amRNSClinical Development Collaboration with Incanthera
21st Dec 20184:41 pmRNSSecond Price Monitoring Extn
21st Dec 20184:36 pmRNSPrice Monitoring Extension
20th Dec 20184:35 pmRNSPrice Monitoring Extension
17th Dec 20187:00 amRNSAppointment of Nominated Adviser
7th Dec 20187:00 amRNSUpdate on Corporate Activities
29th Nov 20184:40 pmRNSSecond Price Monitoring Extn
29th Nov 20184:35 pmRNSPrice Monitoring Extension
28th Nov 20184:40 pmRNSSecond Price Monitoring Extn
28th Nov 20184:35 pmRNSPrice Monitoring Extension
23rd Nov 20184:40 pmRNSSecond Price Monitoring Extn
23rd Nov 20184:35 pmRNSPrice Monitoring Extension
21st Nov 20184:40 pmRNSSecond Price Monitoring Extn
21st Nov 20184:35 pmRNSPrice Monitoring Extension
7th Nov 20184:35 pmRNSPrice Monitoring Extension
1st Nov 20181:38 pmRNSNominated Adviser Status
26th Sep 20187:00 amRNSInterim Results
19th Sep 20187:00 amRNSAppointment of Joint Brokers
7th Sep 20187:00 amRNSCorporate Update
10th Jul 20184:40 pmRNSSecond Price Monitoring Extn
10th Jul 20184:35 pmRNSPrice Monitoring Extension
28th Jun 201812:16 pmRNSResult of AGM
14th Jun 20187:00 amRNSResults of CIDP Pre-Clinical Data
6th Jun 20187:00 amRNSNotice of AGM & Posting of Annual Report
29th May 20187:00 amRNSUpdate on Pivotal Phase III Trial of Lupuzor
29th May 20187:00 amRNSFinal Results
24th Apr 201811:59 amRNSHolding(s) in Company
20th Apr 20188:24 amRNSHolding(s) in Company
19th Apr 20188:05 amRNSHolding(s) in Company
17th Apr 20187:00 amRNSTopline results of Lupuzor Pivotal Phase III Trial
28th Mar 20187:00 amRNSAppointment of Joint Broker
23rd Mar 20187:00 amRNSLupuzor Pivotal Phase III Study Update
5th Mar 20184:13 pmRNSAIM Notice (17)
15th Feb 20187:00 amRNSLondon Investor Evening
9th Feb 20182:00 pmRNSHolding(s) in Company
7th Feb 20189:35 amRNSHolding(s) in Company
5th Feb 20187:00 amRNSHolding(s) in Company
31st Jan 201810:23 amRNSHolding(s) in Company
24th Jan 20187:00 amRNSSuccessful Placing to Raise £10 Million
18th Jan 20187:00 amRNSCompletion of LupuzorT Pivotal Phase III Study
21st Dec 20177:05 amRNSGrant of Options
21st Dec 20177:00 amRNSLast patient completes dosing in LupuzorT Trial
28th Nov 201712:00 pmRNSHolding(s) in Company
24th Nov 20171:32 pmRNSGrant of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.